

Supplemental Table S1: MS patient therapies

	RRMS (<i>n</i>)	Progressive MS (<i>n</i>)
No treatment	5	2
Interferon β (Rebif®)	16	8
Glatiramer acetate (Copaxone®)	1	2
Fingolimod (Gilenya®)	4	1
Natalizumab (Tysabri®)	7	2
Alemtuzumab (Campath®)	1	2

Supplemental Table S2: MS patient disease types per training group

MS TYPE	MIT (<i>n</i> =21)		HIT (<i>n</i> =20)	
	MALE (n)	FEMALE (n)	MALE (n)	FEMALE (n)
RRMS	4	6	7	9
SPMS	5	5	2	2
PPMS	1	0	0	0